No relation between docetaxel administration route and high-grade diarrhea incidence.

ABSTRACT: Oral administration of docetaxel in combination with the CYP3A4 inhibitor ritonavir is used in clinical trials to improve oral bioavailability of docetaxel. Diarrhea was the most commonly observed and dose-limiting toxicity. This study combined preclinical and clinical data and investigated incidence, severity and cause of oral docetaxel-induced diarrhea. In this study, incidence and severity of diarrhea in patients were compared to exposure to orally administered docetaxel. Intestinal toxicity after oral or intraperitoneal administration of docetaxel was further explored in mice lacking Cyp3a and mice lacking both Cyp3a and P-glycoprotein. In patients, severity of diarrhea increased significantly with an increase in AUC and C_max (P = .035 and P = .025, respectively), but not wi

SUBMITTER: Hendrikx JJMA 

PROVIDER: S-EPMC7387127 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature